Validation of a single-pass surgical trajectory to enable AAV2-hAADC infusion into brainstem and mid-brain in nonhuman primate
验证单次手术轨迹,使 AAV2-hAADC 能够输注到非人灵长类动物的脑干和中脑
基本信息
- 批准号:10040048
- 负责人:
- 金额:$ 42.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-15 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAblationAcidsAdverse effectsAdverse eventAffectAmino AcidsAnnual ReportsAreaAwarenessBasal GangliaBilateralBiochemicalBrainBrain DiseasesBrain StemCannulasCarboxy-LyasesCaregiversCell NucleusChildChildhoodChronicClinicalClinical ResearchClinical TrialsCohort AnalysisDOPA decarboxylaseDataDeficiency DiseasesDepositionDiseaseDopamineDopamine AgonistsDyskinetic syndromeDystoniaEmotionalEnzymesEvaluationGene DeliveryGene ExpressionGenesGenetic DiseasesGoalsHomovanillic AcidHumanHydroxyindoleacetic AcidHypokinesiaImpaired cognitionImpairmentInfusion proceduresInheritedInterventionLevodopaLifeLimbic SystemMedicalMidbrain structureMuscle hypotoniaMutationNeurologicNeurologic SymptomsNeurotransmittersNorepinephrineOperative Surgical ProceduresOutcome StudyPathologicPathway interactionsPatientsProceduresProtocols documentationPublic HealthResearchSafetySerious Adverse EventSerotoninSiteSleep disturbancesSocietiesStructureSubstantia nigra structureSymptomsSystemTestingTherapeuticTimeTreatment EfficacyValidationVentral Tegmental AreaViral VectorWritingaromatic L-amino acid decarboxylase deficiency baseburden of illnesscohortcostdorsal raphe nucleusexperimental studygene therapyimprovedloss of function mutationmonoaminemotor symptomnervous system disordernonhuman primatenoradrenergicpars compactaprogramsrecessive genetic traitrecruitvector
项目摘要
PROJECT SUMMARY/ABSTRACT
Aromatic L-amino acid decarboxylase (AADC) deficiency is a rare pediatric genetic disorder in which mutations
in the DOPA decarboxylase gene (DDC) result in a non-functional AADC enzyme that causes the ablation of
dopamine and serotonin synthesis. Affected children suffer prominent motor symptoms, including hypokinesia,
hypotonia, oculogyric crises and dystonia, as well as emotional lability, sleep disturbance and cognitive
impairment. Patients derive little symptomatic benefit from currently available medical therapies. Our long-term
goal is to provide a therapeutic approach to eliminate the neurological signs and symptoms of the disease by
increasing the AADC levels via localized infusion of a viral vector (AAV2) encoding human AADC into affected
nuclei in the brain. In our current exploratory clinical study (NCT02852213), we have treated 9 patients with
AADC deficiency with a single bilateral infusion into the pre-nigral region to restore normal dopamine synthesis
in the basal ganglia and limbic system. Preliminary evaluations from cohorts 1 and 2 have proven this
approach to be safe with only mild and transient dyskinesia about one month and a half after surgery. Marked
reduction or elimination of oculogyric crises has been observed. Biochemical analyses showed an increase in
dopamine metabolite homovanillic acid (HVA), a slight reduction of 3-oxymethyldopa (3-OMD) while serotonin
metabolite 5-hydroxyindolacetic acid (5-HIAA) remained unchanged in all patients. Currently, analyses of these
cohorts, 24 and 12 months after surgery respectively, also showed that there have been no adverse events or
serious adverse events related to the surgical procedure or the vector.
The present proposal seeks to accumulate safety data in nonhuman primates in which a single cannula pass will
enable vector delivery into serotonergic and noradrenergic nuclei as well as the current dopaminergic nuclei.
Data from this study will be used to submit a new IND and recruit more patients for this new procedure.
In our view, the proposed research will have a significant impact on public health. Although AADC deficiency is
a rare pediatric disease, the burden to caregivers and the cost to society is large over the life of the patients not
to mention the plight of the patients themselves. In the larger sense, projects like this will continue to enhance
our ability to treat inherited neurological diseases.
项目概要/摘要
芳香族 L-氨基酸脱羧酶 (AADC) 缺乏症是一种罕见的儿科遗传性疾病,其中突变
多巴脱羧酶基因 (DDC) 中的多巴脱羧酶基因 (DDC) 会产生无功能的 AADC 酶,从而导致
多巴胺和血清素的合成。受影响的儿童会出现明显的运动症状,包括运动功能减退、
肌张力低下、眼部危机和肌张力障碍,以及情绪不稳定、睡眠障碍和认知障碍
损害。患者从目前可用的药物治疗中获得的症状很少。我们的长期
目标是提供一种治疗方法,通过以下方式消除疾病的神经体征和症状:
通过将编码人 AADC 的病毒载体 (AAV2) 局部输注至受影响的患者体内,提高 AADC 水平
大脑中的细胞核。在我们目前的探索性临床研究 (NCT02852213) 中,我们治疗了 9 名患者
AADC 缺乏症可通过单次双侧输注至黑前区域恢复正常的多巴胺合成
在基底神经节和边缘系统中。第 1 组和第 2 组的初步评估证明了这一点
这种方法是安全的,仅在术后一个半月左右出现轻微和短暂的运动障碍。标记
已观察到眼部危机的减少或消除。生化分析显示,
多巴胺代谢物高香草酸 (HVA),轻微减少 3-羟甲基多巴 (3-OMD),同时血清素
所有患者的代谢物 5-羟基吲哚乙酸 (5-HIAA) 均保持不变。目前,对这些
分别在手术后 24 个月和 12 个月的队列也表明没有出现不良事件或
与外科手术或载体相关的严重不良事件。
本提案旨在积累非人类灵长类动物的安全数据,其中单个插管通过即可
使载体能够递送至血清素能和去甲肾上腺素能核以及当前的多巴胺能核。
这项研究的数据将用于提交新的 IND 并招募更多患者进行这项新手术。
我们认为,拟议的研究将对公众健康产生重大影响。尽管 AADC 缺乏
这是一种罕见的儿科疾病,在患者的一生中,护理人员的负担和社会成本都很大
更不用说患者本身的困境了。从更大的意义上讲,此类项目将继续增强
我们治疗遗传性神经系统疾病的能力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Krystof S Bankiewicz其他文献
Krystof S Bankiewicz的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Krystof S Bankiewicz', 18)}}的其他基金
Development of a nanoparticle-based gene editing technology for neurological applications
开发用于神经学应用的基于纳米颗粒的基因编辑技术
- 批准号:
10012948 - 财政年份:2019
- 资助金额:
$ 42.9万 - 项目类别:
Development of a Nanoparticle-Based Gene Editing Technology for Neurological Applications
开发用于神经学应用的基于纳米颗粒的基因编辑技术
- 批准号:
10263159 - 财政年份:2019
- 资助金额:
$ 42.9万 - 项目类别:
Development of a nanoparticle-based gene editing technology for neurological applications
开发用于神经学应用的基于纳米颗粒的基因编辑技术
- 批准号:
9810326 - 财政年份:2019
- 资助金额:
$ 42.9万 - 项目类别:
Development of a Nanoparticle-Based Gene Editing Technology for Neurological Applications
开发用于神经学应用的基于纳米颗粒的基因编辑技术
- 批准号:
10669525 - 财政年份:2019
- 资助金额:
$ 42.9万 - 项目类别:
Development of a nanoparticle-based gene editing technology for neurological applications
开发用于神经学应用的基于纳米颗粒的基因编辑技术
- 批准号:
10619048 - 财政年份:2019
- 资助金额:
$ 42.9万 - 项目类别:
A Safety and Efficacy Study of AAV2-hAADC for AADC Deficiency
AAV2-hAADC 治疗 AADC 缺乏症的安全性和有效性研究
- 批准号:
10505606 - 财政年份:2016
- 资助金额:
$ 42.9万 - 项目类别:
A Safety and Efficacy study of AAV2-hAADC for AADC deficiency
AAV2-hAADC 治疗 AADC 缺乏症的安全性和有效性研究
- 批准号:
10299327 - 财政年份:2016
- 资助金额:
$ 42.9万 - 项目类别:
Translational AAV Delivery Platform to the Brain
大脑转化 AAV 传递平台
- 批准号:
8513428 - 财政年份:2011
- 资助金额:
$ 42.9万 - 项目类别:
Translational AAV Delivery Platform to the Brain
大脑转化 AAV 传递平台
- 批准号:
8696895 - 财政年份:2011
- 资助金额:
$ 42.9万 - 项目类别:
Translational AAV Delivery Platform to the Brain
大脑转化 AAV 传递平台
- 批准号:
8084288 - 财政年份:2011
- 资助金额:
$ 42.9万 - 项目类别:
相似海外基金
Targeted ablation of cerebral atherosclerosis using supramolecular self-assembly
利用超分子自组装靶向消融脑动脉粥样硬化
- 批准号:
24K21101 - 财政年份:2024
- 资助金额:
$ 42.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
心房細動に対するPulsed Field Ablationの組織創傷治癒過程を明らかにする網羅的研究
阐明房颤脉冲场消融组织伤口愈合过程的综合研究
- 批准号:
24K11201 - 财政年份:2024
- 资助金额:
$ 42.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
遅延造影心臓MRIによる心房細動Ablation冷却効果の比較:28 vs. 31 mm Cryoballoon
使用延迟对比增强心脏 MRI 比较房颤消融冷却效果:28 毫米与 31 毫米 Cryoballoon
- 批准号:
24K11281 - 财政年份:2024
- 资助金额:
$ 42.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
InSPACE-VT_Development and Validation of Virtual Pace Mapping to Guide Catheter Ablation of Ventricular Tachycardia
InSPACE-VT_虚拟起搏测绘的开发和验证以指导室性心动过速导管消融
- 批准号:
EP/Z001145/1 - 财政年份:2024
- 资助金额:
$ 42.9万 - 项目类别:
Fellowship
CAREER: Heat Penetration Depth and Direction Control with Closed-Loop Device for Precision Ablation
职业:利用闭环装置控制热穿透深度和方向,实现精确烧蚀
- 批准号:
2338890 - 财政年份:2024
- 资助金额:
$ 42.9万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334777 - 财政年份:2024
- 资助金额:
$ 42.9万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334775 - 财政年份:2024
- 资助金额:
$ 42.9万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334776 - 财政年份:2024
- 资助金额:
$ 42.9万 - 项目类别:
Continuing Grant
Cryo laser-ablation system (157+193nm) with 'triple-quad' plasma mass spectrometer, Cryo-LA-ICPMS/MS
带有“三重四极杆”等离子体质谱仪、Cryo-LA-ICPMS/MS 的冷冻激光烧蚀系统 (157 193nm)
- 批准号:
515081333 - 财政年份:2023
- 资助金额:
$ 42.9万 - 项目类别:
Major Research Instrumentation
MRI: Acquisition of a Laser Ablation - Inductively Coupled Plasma - Triple Quadrupole - Mass Spectrometer (LA-ICP-QQQ-MS) System For Research and Education
MRI:获取用于研究和教育的激光烧蚀 - 电感耦合等离子体 - 三重四极杆 - 质谱仪 (LA-ICP-MS/MS) 系统
- 批准号:
2320040 - 财政年份:2023
- 资助金额:
$ 42.9万 - 项目类别:
Standard Grant